Jeffrey Yachnin

Publications
CV
Public outreach and news

Articles

Article: PROSTATE. 2023;83(10):950-961

Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer

Vardaki I; Ozcan SS; Fonseca P; Lin S-H; Logothetis CJ; Yachnin J; Ullen A; Panaretakis T
Article: NATURE CANCER. 2022;3(2):251-261

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Article: LANCET ONCOLOGY. 2022;23(1):53-64

Dabrafenib plus trametinib in patients with BRAF^V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz R-D; Blay J-Y; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2021;48(10):3325-3334

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullen A
Article: CLINICAL THERAPEUTICS. 2021;43(6):1092-1111

Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors

Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau H-T; Basque J-R; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(5):1189-1199

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Irenaeus SMM; Nielsen D; Ellmark P; Yachnin J; Deronic A; Nilsson A; Norlen P; Veitonmaki N; Wennersten CS; Ullenhag GJ
Article: ONCOLOGIST. 2019;24(6):745-e213

Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial

Shah C-H; Pappot H; Agerbaek M; Holmsten K; Jaderling F; Yachnin J; Gryback P; von der Maase H; Ullen A
Article: CLINICAL CANCER RESEARCH. 2019;25(6):1766-1773

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam P-J; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullen A; Yachnin J; Gronberg H; Van Laere SJ; Lindberg J; Dirix LY
Article: LANCET ONCOLOGY. 2019;20(3):383-393

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial

de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels J-P; Arkenau H-T; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Srensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Article: GENOME MEDICINE. 2018;10(1):85

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam P-J; Van den Eynden G; Rutten A; Aly M; Nordstrom T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullen A; Yachnin J; Dirix L; Gronberg H; Lindberg J
Article: JAMA ONCOLOGY. 2018;4(9):1199-1206

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen P-L; Lindman H
Article: EUROPEAN JOURNAL OF CANCER. 2018;97:33-40

Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)

Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullen A
Article: PLOS ONE. 2016;11(12):e0168153

The In Vitro Stability of Circulating Tumour DNA

Diaz EH; Yachnin J; Gronberg H; Lindberg J
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2016;5:29877

Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells

Ronquist KG; Sanchez C; Dubois L; Chioureas D; Fonseca P; Larsson A; Ullen A; Yachnin J; Ronquist G; Panaretakis T
Article: ONCOTARGET. 2015;6(25):21740-21754

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel

Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullen A; Yachnin J; Nilsson S; Panaretakis T
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2014;73(6):1241-1252

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.

Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels J-P; Conkright W; Sharma S; Soetekouw PMMB; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
Article: VACCINE. 2013;31(37):3843-3848

DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer

Eriksson F; Totterman T; Maltais A-K; Pisa P; Yachnin J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann S; Bykov VJN; Ali D; Andren O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE. 2009;8:2

Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.

Broomand A; Jerremalm E; Yachnin J; Ehrsson H; Elinder F
Article: LANCET ONCOLOGY. 2007;8(7):587-594

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study

Nilsson S; Franzen L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernas B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2006;28(4):278-283

Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate

Jerremalm E; Wallin I; Yachnin J; Ehrsson H
Article: CANCER LETTERS. 2002;180(2):191-194

Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin

Videhult P; Yachnin J; Jerremalm E; Lewensohn R; Ehrsson H
Article: MEDICAL ONCOLOGY. 2002;19(4):261-265

Pharmacokinetics of oxaliplatin in humans

Ehrsson H; Wallin I; Yachnin J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;283(4):726-731

DNA-dependent protein kinase is inhibited by trifluoperazine

Eriksson Å; Yachnin J; Lewensohn R; Nilsso A
Show more

All other publications

Corrigendum: NATURE CANCER. 2022;3(5):649

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology (vol 3, pg 251, 2022)

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Editorial comment: JCO PRECISION ONCOLOGY. 2021;5:974-980

Discordant Reporting of a Previously CD Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma

Kordes M; Tamborero D; Lagerstedt-Robinson K; Yachnin J; Rosenquist R; Lohr J-M; Liljefors MG
Letter: NATURE MEDICINE. 2020;26(7):992-994

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Baird R; Brana I; De Petris L; Yachnin J; Massard C; Opdam FL; Schlenk R; Vernieri C; Garralda E; Masucci M; Villalobos X; Chavarria E; Calvo F; Frohling S; Eggermont A; Apolone G; Voest EE; Caldas C; Tabernero J; Ernberg I; Rodon J; Lehtio J
Letter: JAMA ONCOLOGY. 2019;5(7):1060-1062

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

De Laere B; Rajan P; Gronberg H; Dirix L; Lindberg J; Mayrhofer M; Whitington T; van Dam P-J; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoela L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden G; Rutten A; Del Favero J; Rantalainen M; Sleijfer S; Ullen A; Yachnin J; Van Laere S; De laere L; Develter T; Vantieghem S; Herman S; Coifs G; Lamotte V; Boumans A; Baitar A; Haeck R; Wallays G
Letter: ACTA ONCOLOGICA. 2018;57(5):700-703

Primary bone lymphoma presenting as skeletal lesions in a patient recently treated for prostate cancer

Kordes M; Yachnin J
Thesis / dissertation: 2005

Chemical, pharmacokinetic and biological aspects of platinum-based drugs

Yachnin, Jeffrey R

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2025

Degrees and Education

Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2005

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI